Oxford Cannabinoid Technologies Holdings Plc operates as a biopharmaceutical company, specializing in the discovery, development, and eventual market launch of cannabinoid-derived prescription medications. Its leading experimental drug, OCT461201, is a selective CB2 receptor agonist formulated as a solid oral dose. This compound is currently in the early, pre-clinical phase of development, being explored for its potential to alleviate visceral pain linked to Irritable Bowel Syndrome (IBS), alongside various neuropathic pain disorders like post-herpetic neuralgia.